Cabergoline and Dementia - a phase IV clinical study of FDA data

Summary:

Dementia is reported as a side effect among people who take Cabergoline (cabergoline), especially for people who are male, 60+ old, have been taking the drug for 2 - 5 years also take Simvastatin, and have Abdominal discomfort.

The phase IV clinical study analyzes which people have Dementia when taking Cabergoline. It is created by eHealthMe based on reports of 5,946 people who have side effects when taking Cabergoline from the FDA, and is updated regularly.

What is Cabergoline?

Cabergoline has active ingredients of cabergoline. It is often used in prolactinoma. eHealthMe is studying from 6,257 Cabergoline users. Check the latest studies of Cabergoline.

What is Dementia?

Dementia (madness) is found to be associated with 1,204 drugs and 1,809 conditions by eHealthMe. Check the latest studies of Dementia.

On Aug, 10, 2026

5,946 people reported to have side effects when taking Cabergoline.
Among them, 34 people (0.57%) have Dementia.

Among these 34 people:

How long have people been on Cabergoline when they have Dementia? *

What is the gender of people who have Dementia when taking Cabergoline? *

female: 29.03 %
male: 70.97 %

What is the age of people who have Dementia when taking Cabergoline? *

What are other drugs people take besides Cabergoline? *

What are other side effects people have besides Dementia? *

Malaise (a feeling of general discomfort or uneasiness): 18 people, 52.94%
Rashes (redness): 16 people, 47.06%
Abdominal Pain: 16 people, 47.06%
Gastrointestinal Pain: 16 people, 47.06%
Inflammation: 16 people, 47.06%
Abdominal Discomfort: 15 people, 44.12%
Groin Pain: 15 people, 44.12%
Feeling Abnormal: 15 people, 44.12%
Lung Neoplasm Malignant (cancer tumour of lung): 15 people, 44.12%
Diarrhea: 15 people, 44.12%

What are the existing conditions these people have? *

Abdominal Discomfort: 17 people, 50.00%
Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 16 people, 47.06%
Depression: 16 people, 47.06%
Empty Sella Syndrome (pituitary gland shrinks or becomes flattened): 16 people, 47.06%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 15 people, 44.12%
Urinary Tract Infection: 11 people, 32.35%
Itching: 9 people, 26.47%
Reflux Laryngitis (voice disorder caused by backflow of stomach fluids to the throat and voice box area): 9 people, 26.47%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 8 people, 23.53%
Parkinson's Disease: 6 people, 17.65%

* Approximation only. Some reports may have incomplete information.

Do you take Cabergoline and have Dementia?

- Check whether Dementia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cabergoline:

Cabergoline (6,257 reports)

Dementia treatments and more:

Dementia (44,271 reports)

Browse all side effects of Cabergoline:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dementia:

Dementia (1,204 drugs)

Browse all the conditions that are associated with Dementia:

Dementia (1,809 conditions)

Related publications that referenced our studies

Gürbüz F, Ya?c?-Küpeli B, K?r Y, Yüksel B, Zorludemir S, Gürbüz BB, Küpeli S, "The first report of cabergoline-induced immune hemolytic anemia in an adolescent with prolactinoma", Journal of Pediatric Endocrinology and Metabolism, 2014 Jan .
Harris YT, Harris AZ, "Cabergoline associated with first episode mania", Psychosomatics, 2012 Jan .
Gürbüz F, Ya?c?-Küpeli B, K?r Y, Yüksel B, Zorludemir S, Gürbüz BB, Küpeli S, "The first report of cabergoline-induced immune hemolytic anemia in an adolescent with prolactinoma", Journal of Pediatric Endocrinology and Metabolism, 2014 Jan .
Harris YT, Harris AZ, "Cabergoline associated with first episode mania", Psychosomatics, 2012 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on cabergoline (the active ingredients of Cabergoline) and Cabergoline (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.